Brain-derived extracellular vesicle (EV) biomarkers represent a promising frontier for liquid biopsy development targeting the nervous system. They offer strong potential for enabling minimally ...
Summit (TM) 2.0 is a CSF-based liquid biopsy assay designed to enable comprehensive genomic profiling for characterization of CNS tumors. CNS malignancies present unique diagnostic challenges, as ...
Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...
Supported by the National Institute of Health T32GM145408 to C.R-C. Supported by NINDS R61 NS122096, NCI R37CA27685, the Mayo Clinic Center for Individualized Medicine and CCaTS award UL1TR002377, ...
In this Innovation Spotlight, Dan Levangie, president and chief executive officer of CereVasc, discusses a new treatment strategy for NPH using an endovascularly implantable CSF shunt that minimizes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results